QuantuMDx launches New PCR Respiratory Panel
- New multiplex panel can detect SARS-CoV-2, Flu A, Flu B & RSV at the Point of Need
- Accurate PCR results delivered in 35 minutes
NEWCASTLE UPON TYNE, UK, 26 May 2022. QuantuMDx Group Limited (‘QuantuMDx’ or the ‘Company’), a UK-based developer of transformational point-of-care diagnostics, today announces the launch of its new respiratory panel test; Q-POC™ SARS-CoV-2, Flu A/B & RSV Assay.
The Q-POC™ respiratory panel test builds on the Q-POC™ SARS-CoV-2 test launched in 2021, substantially expanding the Q-POC™ platform and its multiplex capabilities and providing customers with rapid, point of care testing in a range of healthcare settings.
The Q-POC™ SARS-CoV-2, Flu A/B & RSV Assay has been designed with the most up to date information on sequences of SARS-CoV-2, Flu A, Flu B & RSV, to ensure coverage of all known sequences present in publicly available databases.
The PCR Respiratory Panel will provide a differential diagnosis and enable rapid triage and effective treatment strategies, particularly in at-risk groups of patients, in 35 minutes at the Point of Need. Flu, RSV and SARS-CoV-2 therapies are specific to the disease-causing virus and therefore identification of each individual pathogen is required. Moreover, early identification of co-infection is particularly important in at risk groups or can help to shorten treatment and hospital stays which also leads to lower overall costs.
This assay is…
